Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Technical Analysis
$8.42▲4.99%
Market is closed - opens 7 PM, 14 Sep 2026
Insights
- Eupraxia Pharmaceuticals Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Eupraxia Pharmaceuticals Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Eupraxia Pharmaceuticals Inc. stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Eupraxia Pharmaceuticals Inc. stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 66.61 | Sell |
Stochastic | 92.07, 81.2 | Neutral |
Ultimate Oscillator | 60.57 | Neutral |
Stochastic Relative Strength Index | 81.67, 84.42 | Sell |
Moving Average Convergence Divergence | 0.41, 0.28 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.56 | Buy |
20 | 7.3 | Buy |
50 | 6.8 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.79 | Buy |
20 | 7.43 | Buy |
50 | 7.02 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 7.81 | Buy |
20 | 7.53 | Buy |
50 | 6.99 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 8.24 | Buy |
20 | 7.93 | Buy |
50 | 7.31 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 8.39 | Buy |
20 | 8.19 | Buy |
50 | 7.66 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 8.73 |
Resistance L2 | 8.51 |
Resistance L1 | 8.27 |
Pivot Point | 8.05 |
Support L1 | 7.81 |
Support L2 | 7.59 |
Support L3 | 7.35 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.